ProMisE联合超声与人口学特征术前预测子宫内膜癌复发或进展
本研究纳入339例子宫内膜癌患者,评估人口学、超声变量及ProMisE分子分型对术前预测肿瘤复发或进展的能力。结果显示,包含ProMisE分型、年龄、腰围及超声肿瘤扩展和径线的模型预测能力(AUC 0.89)优于ESMO术前和术后风险分类,且非p53 abn亚型合并肿瘤<2cm者复发风险极低(1.8%)。
要点
- ProMisE分子分型联合超声和人口学特征可提高术前复发风险预测。
- p53 abn亚型复发或进展率达45%,显著高于其他亚型。
- 非p53 abn且肿瘤<2cm者复发风险仅1.8%,可识别低危人群。
核心结论
- 人口学特征、超声表现与ProMisE分型联合的术前预测能力优于ESMO分类。
- p53状态联合超声肿瘤大小有助于术前识别低复发风险人群。
研究设计与样本
- 前瞻性国际子宫内膜肿瘤分析4研究或相同方案的单中心研究,纳入339例经组织学确诊的子宫内膜癌患者,术前由专家行经阴道超声。
- 根据组织学类型、FIGO分级和分期分类,并进行分子分析分为四个ProMisE亚型:POLE EDM、MMR-D、p53 wt和p53 abn。
- 采用Cox回归分析预后因素,逻辑回归和ROC曲线评估术前预测能力,并与ESMO术前和术后风险分类比较。
主要发现
- 中位随访58个月(IQR 48-71,范围0-102),51/339(15%)发生复发或进展。
- 各ProMisE亚型复发或进展率:MMR-D 14%,POLE EDM 8%,p53 wt 9%,p53 abn 45%。
- 多变量分析中,年龄、腰围、ProMisE亚型、超声肿瘤扩展和AP直径与复发或进展相关。
- 包含ProMisE亚型、年龄、腰围、超声肿瘤扩展和大小的模型AUC为0.89(95%CI 0.85-0.93),与包含组织学类型、分级等的模型(AUC 0.88,95%CI 0.83-0.92)相当。
- 该模型预测能力优于ESMO术前分类(AUC 0.74,95%CI 0.67-0.82;P<0.01)和术后分类(AUC 0.79,95%CI 0.72-0.86;P<0.01)。
关键数值与推荐
- ProMisE分型包括POLE EDM、MMR-D、p53 wt和p53 abn四个亚型。
- ESMO术前分类基于肌层浸润深度、组织学类型和分级;术后分类基于组织学类型、分级、手术分期和淋巴血管间隙浸润。
- 超声肿瘤大小以AP直径<2cm vs ≥2cm分层。
- 预测3年内复发或进展的AUC:联合模型0.89,ESMO术前0.74,ESMO术后0.79。
临床怎么用
- 术前可结合ProMisE分子分型、年龄、腰围及超声肿瘤特征进行复发风险分层。
- 对非p53 abn且超声肿瘤<2cm者可识别为极低危人群,可能避免过度治疗。
- p53 abn亚型患者复发风险高,需加强术后监测和辅助治疗考虑。
局限性
- 单中心研究,样本量339例,需外部验证。
- 随访时间中位58个月,更长随访可能影响结果。
- ProMisE分型需肿瘤组织,术前应用依赖活检样本可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the ability of demographic and sonographic variables and the Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) classification to predict preoperatively tumor recurrence or progression in women with endometrial cancer. METHODS: The study included 339 women with histologically confirmed endometrial cancer who underwent expert transvaginal ultrasound in a single center before surgery as part of the prospective International Endometrial Tumor Analysis 4 study or who were evaluated using the same protocol. The tumors were classified according to histotype, FIGO (International Federation of Gynecology and Obstetrics) grade and FIGO stage. In addition, molecular analysis was performed for classification into the four ProMisE subtypes: polymerase-ϵ exonuclease domain mutations (POLE EDM), mismatch repair proteins deficiency (MMR-D), protein 53 wild type (p53 wt) and protein 53 abnormal (p53 abn). Demographic and preoperative sonographic characteristics, tumor recurrence or progression and survival were compared between the ProMisE subgroups. Cox regression analysis was used to identify prognostic factors associated with recurrence or progression, using univariable models to study crude associations and multivariable models to study adjusted associations. Logistic regression and receiver-operating-characteristics (ROC)-curve analysis were used to assess the predictive ability of the preoperative prognostic factors regarding recurrence or progression of cancer within 3 years after surgery, and to compare their predictive ability to that of the European Society for Medical Oncology (ESMO) preoperative (based on depth of myometrial invasion, histotype and grade) and postoperative (based on histotype, grade, surgical stage and lymphovascular space invasion) risk classifications. In a separate subanalysis, cases were stratified according to ProMisE p53 abn status (present vs absent) and sonographic tumor size (anteroposterior (AP) diameter < 2 cm vs ≥ 2 cm). RESULTS: Median follow-up time from surgery was 58 months (interquartile range, 48-71 months; range, 0-102 months). Recurrence or progression of cancer occurred in 51/339 (15%) women, comprising 14% of those with MMR-D, 8% of those with POLE EDM, 9% of those with p53 wt and 45% of those with p53 abn ProMisE subtype. On multivariable analysis, age, waist circumference, ProMisE subtype and tumor extension and AP diameter on ultrasound were associated with tumor recurrence or progression. A multivariable model comprising ProMisE subtype, age, waist circumference and sonographic tumor extension and size (area under the ROC curve (AUC), 0.89 (95% CI, 0.85-0.93)) had comparable ability to predict tumor recurrence/progression to that of a multivariable model comprising histotype, grade, age, waist circumference and sonographic tumor extension and size (AUC, 0.88 (95% CI, 0.83-0.92)), and better predictive ability than both the preoperative (AUC, 0.74 (95% CI, 0.67-0.82); P < 0.01) and postoperative (AUC, 0.79 (95% CI, 0.72-0.86); P < 0.01) ESMO risk classifications. Women with a combination of non-p53 abn subtype and tumor size < 2 cm (164/339 (48%)) had a very low risk (1.8%) of tumor recurrence or progression. CONCLUSIONS: The combination of demographic characteristics, sonographic findings and ProMisE subtype had better preoperative predictive ability for tumor recurrence or progression than did the ESMO classification, supporting their use in the preoperative risk stratification of women with endometrial cancer. The combination of p53 status with ultrasound tumor size has the potential to identify preoperatively a large group of women with a very low risk of recurrence or progression. © 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology. - Legal Statement: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
引用
- Eriksson LSE, Nastic D, Lindqvist PG, et al. Combination of Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer. Ultrasound Obstet Gynecol. 2021. PMID: 33314410. doi:10.1002/uog.23573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。